UNLABELLED: Risk-adjusted health outcomes are often used to measure the quality of hospital care, yet the optimal approach in patients with liver disease is unclear. We sought to determine whether assessments of illness severity, defined as risk for in-hospital mortality, vary across methods in patients with cirrhosis. We identified 258,731 patients with cirrhosis hospitalized in the Nationwide Inpatient Sample between 2002 and 2005. The performance of four common risk adjustment methods (the Charlson/Deyo and Elixhauser comorbidity algorithms, Disease Staging, and All Patient Refined Diagnosis Related Groups [APR-DRGs]) for predicting in-hospital mortality was determined using the c-statistic. Subgroup analyses were conducted according to a primary versus secondary diagnosis of cirrhosis and in homogeneous patient subgroups (hepatic encephalopathy, hepatocellular carcinoma, congestive heart failure, pneumonia, hip fracture, and cholelithiasis). Patients were also ranked according to the probability of death as predicted by each method, and rankings were compared across methods. Predicted mortality according to the risk adjustment methods agreed for only 55%-67% of patients. Similarly, performance of the methods for predicting in-hospital mortality varied significantly. Overall, the c-statistics (95% confidence interval) for the Charlson/Deyo and Elixhauser algorithms, Disease Staging, and APR-DRGs were 0.683 (0.680-0.687), 0.749 (0.746-0.752), 0.832 (0.829-0.834), and 0.875 (0.873-0.878), respectively. Results were robust across diagnostic subgroups, but performance was lower in patients with a primary versus secondary diagnosis of cirrhosis. CONCLUSION: Mortality analyses in patients with cirrhosis require sensitivity to the method of risk adjustment. Because different methods often produce divergent severity rankings, analyses of provider-specific outcomes may be biased depending on the method used.
UNLABELLED: Risk-adjusted health outcomes are often used to measure the quality of hospital care, yet the optimal approach in patients with liver disease is unclear. We sought to determine whether assessments of illness severity, defined as risk for in-hospital mortality, vary across methods in patients with cirrhosis. We identified 258,731 patients with cirrhosis hospitalized in the Nationwide Inpatient Sample between 2002 and 2005. The performance of four common risk adjustment methods (the Charlson/Deyo and Elixhauser comorbidity algorithms, Disease Staging, and All Patient Refined Diagnosis Related Groups [APR-DRGs]) for predicting in-hospital mortality was determined using the c-statistic. Subgroup analyses were conducted according to a primary versus secondary diagnosis of cirrhosis and in homogeneous patient subgroups (hepatic encephalopathy, hepatocellular carcinoma, congestive heart failure, pneumonia, hip fracture, and cholelithiasis). Patients were also ranked according to the probability of death as predicted by each method, and rankings were compared across methods. Predicted mortality according to the risk adjustment methods agreed for only 55%-67% of patients. Similarly, performance of the methods for predicting in-hospital mortality varied significantly. Overall, the c-statistics (95% confidence interval) for the Charlson/Deyo and Elixhauser algorithms, Disease Staging, and APR-DRGs were 0.683 (0.680-0.687), 0.749 (0.746-0.752), 0.832 (0.829-0.834), and 0.875 (0.873-0.878), respectively. Results were robust across diagnostic subgroups, but performance was lower in patients with a primary versus secondary diagnosis of cirrhosis. CONCLUSION: Mortality analyses in patients with cirrhosis require sensitivity to the method of risk adjustment. Because different methods often produce divergent severity rankings, analyses of provider-specific outcomes may be biased depending on the method used.
Authors: Jessica L Mellinger; Caroline R Richardson; Amit K Mathur; Michael L Volk Journal: Clin Gastroenterol Hepatol Date: 2014-09-28 Impact factor: 11.382
Authors: Erin Renae Weeda; Brandon Scott Nicoll; Craig Ian Coleman; Anna Sharovetskaya; William Leslie Baker Journal: Intern Emerg Med Date: 2016-08-17 Impact factor: 3.397
Authors: Jack X Q Pang; Erin Ross; Meredith A Borman; Scott Zimmer; Gilaad G Kaplan; Steven J Heitman; Mark G Swain; Kelly Burak; Hude Quan; Robert P Myers Journal: Can J Gastroenterol Hepatol Date: 2015-04
Authors: Jack X Q Pang; Faruq Pradhan; Scott Zimmer; Sophia Niu; Pam Crotty; Jenna Tracey; Christopher Schneider; Steven J Heitman; Gilaad G Kaplan; Mark G Swain; Robert P Myers Journal: Can J Gastroenterol Hepatol Date: 2014-03
Authors: Christopher C Stahl; Patrick B Schwartz; Glen E Leverson; James R Barrett; Taylor Aiken; Alexandra W Acher; Sean M Ronnekleiv-Kelly; Rebecca M Minter; Sharon M Weber; Daniel E Abbott Journal: Surgery Date: 2020-04-26 Impact factor: 3.982
Authors: Charles M Psoinos; Julie M Flahive; Joshua J Shaw; Youfu Li; Sing Chau Ng; Jennifer F Tseng; Heena P Santry Journal: Surgery Date: 2013-02-27 Impact factor: 3.982
Authors: John H Holden; Hani Shamseddeen; Amy W Johnson; Benjamin Byriel; Kavitha Subramoney; Yao-Wen Cheng; Akira Saito; Marwan Ghabril; Naga Chalasani; Greg A Sachs; Eric S Orman Journal: J Palliat Med Date: 2020-02-24 Impact factor: 2.947
Authors: Jin Hee Shin; Mathias Worni; Anthony W Castleberry; Ricardo Pietrobon; Philip A Omotosho; Mina Silberberg; Truls Østbye Journal: Obes Surg Date: 2013-05 Impact factor: 4.129